Literature DB >> 28581398

ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Sree Rodda1, W James Morris2, Jeremy Hamm3, Graeme Duncan4.   

Abstract

PURPOSE: To report the patient-reported health-related quality of life (HR-QoL) outcomes for a multicenter randomized trial evaluating the safety and efficacy of 2 different techniques for dose escalation. METHODS AND MATERIALS: A total of 357 men with intermediate- and high-risk prostate cancer were stratified by risk group and randomized (1:1) to either a dose-escalated external beam (DE-EBRT) boost (n=177) or a low-dose-rate prostate brachytherapy (LDR-PB) boost (n=180) as part of combined modality therapy. The HR-QoL was assessed using the SF36v2 questionnaire, with additional scales for urinary, bowel, and sexual function. Date of starting androgen deprivation therapy was considered time zero, the median follow-up of 6 years. Scales were scored from 0 to 100; a decline in a mean score ≥10 compared with baseline was considered a clinically significant decline. This was an intent-to-treat analysis.
RESULTS: Mean domain scores at baseline were well balanced between the 2 treatment arms. A clinically significant decline in mean scores in both the arms compared with baseline was noted for role physical (DE-EBRT [-11.4] and LDR-PB [-15.3]) and sexual function scale (DE-EBRT [-15.1] and LDR-PB [-19.2]). There was a significantly larger drop in mean scores in the LDR-PB group compared with the DE-EBRT group for physical function (-15.3 vs -6.9; P=.03), urinary function (-3.6 vs -0.5; P=.04).
CONCLUSION: At 6 years' follow up, there were no significant differences in mean scores in 9 of 11 scales compared with baseline in both arms. A clinically significant decline in mean scores was noted in both arms for role physical and sexual function scales. There was a statistically significant decline in physical function and urinary function scales in the LDR-PB arm compared with the DE-EBRT arm. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28581398     DOI: 10.1016/j.ijrobp.2017.02.027

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Management of Lower Urinary Tract Symptoms after Prostate Radiation.

Authors:  Pansy Uberoi; Charlton A Smith; Alvaro Lucioni
Journal:  Curr Urol Rep       Date:  2021-05-27       Impact factor: 3.092

2.  Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Authors:  Amar U Kishan; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Kiri A Sandler; Richard G Stock; Gregory S Merrick; D Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Andrew J Stephenson; Eric A Klein; Daniel Y Song; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Johnathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King
Journal:  JAMA       Date:  2018-03-06       Impact factor: 56.272

3.  Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

Authors:  William A Hall; Snehal Deshmukh; Deborah W Bruner; Jeff M Michalski; James A Purdy; Walter Bosch; Jean-Paul Bahary; Maltibehn P Patel; Matthew B Parliament; Michael I Lock; Harold Y Lau; Luis Souhami; Scot A Fisher; Young Kwok; Michael J Seider; Eric Vigneault; Seth A Rosenthal; Gary S Gustafson; Hiram A Gay; Stephanie L Pugh; Howard M Sandler; Benjamin Movsas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-01-01       Impact factor: 7.038

Review 4.  Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.

Authors:  Edina C Wang; W Robert Lee; Andrew J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-10-06       Impact factor: 5.455

5.  Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.

Authors:  Achiraya Teyateeti; Craig Grossman; Marisa A Kollmeier; Megan Fiasconaro; Margaret Hopkins; Sean McBride; Daniel Gorovets; Daniel Shasha; Gilad Cohen; Zhigang Zhang; David J Lesser; Antonio Damato; Michael J Zelefsky
Journal:  BJU Int       Date:  2021-09-02       Impact factor: 5.969

Review 6.  Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination.

Authors:  Sung Uk Lee; Kwan Ho Cho
Journal:  Radiat Oncol J       Date:  2017-09-29

Review 7.  Low dose rate prostate brachytherapy.

Authors:  Bradley J Stish; Brian J Davis; Lance A Mynderse; Robert H McLaren; Christopher L Deufel; Richard Choo
Journal:  Transl Androl Urol       Date:  2018-06

Review 8.  Salvage therapy for prostate cancer after radical prostatectomy.

Authors:  Nicholas G Zaorsky; Jeremie Calais; Stefano Fanti; Derya Tilki; Tanya Dorff; Daniel E Spratt; Amar U Kishan
Journal:  Nat Rev Urol       Date:  2021-08-06       Impact factor: 14.432

9.  Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.

Authors:  Takuji Tsubokura; Hideya Yamazaki; Koji Masui; Naomi Sasaki; Daisuke Shimizu; Gen Suzuki; Satoaki Nakamura; Kei Yamada; Koji Okihara; Takumi Shiraishi; Ken Yoshida; Tatsuyuki Nishikawa; Haruumi Okabe
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

10.  Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.

Authors:  Lindsay M Burt; Dennis C Shrieve; Jonathan D Tward
Journal:  Adv Radiat Oncol       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.